KR20150004885A - 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 - Google Patents

파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 Download PDF

Info

Publication number
KR20150004885A
KR20150004885A KR1020147033000A KR20147033000A KR20150004885A KR 20150004885 A KR20150004885 A KR 20150004885A KR 1020147033000 A KR1020147033000 A KR 1020147033000A KR 20147033000 A KR20147033000 A KR 20147033000A KR 20150004885 A KR20150004885 A KR 20150004885A
Authority
KR
South Korea
Prior art keywords
cyclopropylmethoxy
dichloro
pyridine
methoxy
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147033000A
Other languages
English (en)
Korean (ko)
Inventor
필립 델레이-고예
끌레르 델고르쥬
크리스틴 메네
질 포우옹
크리스틴 라비네-트릴로우
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 filed Critical 사노피
Publication of KR20150004885A publication Critical patent/KR20150004885A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR1020147033000A 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도 Ceased KR20150004885A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
FR0702853 2007-04-19
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020097021593A Division KR101503942B1 (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도

Publications (1)

Publication Number Publication Date
KR20150004885A true KR20150004885A (ko) 2015-01-13

Family

ID=38712405

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147033000A Ceased KR20150004885A (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
KR1020097021593A Expired - Fee Related KR101503942B1 (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020097021593A Expired - Fee Related KR101503942B1 (ko) 2007-04-19 2008-04-16 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR20150004885A (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104955808A (zh) * 2012-11-28 2015-09-30 赛诺菲 4-(环丙基甲氧基)-n-(3,5-二氯-1-氧化吡啶-4-基)-5-甲氧基吡啶-2-甲酰胺的晶型的制备方法以及晶型
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
EP1370211A4 (en) * 2001-03-02 2005-02-09 Bristol Myers Squibb Co SIMULTANEOUS ADMINISTRATION OF MELANOCORTIN RECEPTOR AGONISTS AND A PHOSPHODIESTERASE HEMMER FOR THE TREATMENT OF DISEASES RELATED TO CYCLIC AMP
AU2003281219A1 (en) * 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
AU2004220456B2 (en) * 2003-03-12 2010-10-14 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
CA2684174C (fr) 2014-02-25
FR2915100A1 (fr) 2008-10-24
PT2146714E (pt) 2011-09-02
JO2678B1 (en) 2013-03-03
CA2684174A1 (fr) 2008-12-04
ZA200907251B (en) 2011-04-28
ATE513548T1 (de) 2011-07-15
EP2146714B1 (fr) 2011-06-22
CN101663035B (zh) 2012-06-20
US20100130554A1 (en) 2010-05-27
HK1141725A1 (en) 2010-11-19
HRP20110666T1 (hr) 2011-10-31
KR20090130059A (ko) 2009-12-17
UY31035A1 (es) 2008-11-28
BRPI0810444A2 (pt) 2016-05-31
CN101663035A (zh) 2010-03-03
DK2146714T3 (da) 2011-10-10
SI2146714T1 (sl) 2011-10-28
ES2367408T3 (es) 2011-11-03
EA200970970A1 (ru) 2010-02-26
JP5386478B2 (ja) 2014-01-15
CL2008001136A1 (es) 2009-01-16
FR2915100B1 (fr) 2009-06-05
MY148092A (en) 2013-02-28
CY1111840T1 (el) 2015-10-07
TWI439269B (zh) 2014-06-01
AR066108A1 (es) 2009-07-22
AU2008257322A1 (en) 2008-12-04
KR101503942B1 (ko) 2015-03-18
TW200911247A (en) 2009-03-16
IL201448A (en) 2014-08-31
WO2008145841A1 (fr) 2008-12-04
MX2009011284A (es) 2009-11-02
RS51869B (sr) 2012-02-29
EA019194B1 (ru) 2014-01-30
ME00935B (me) 2012-06-20
PA8776801A1 (es) 2008-11-19
AU2008257322B2 (en) 2013-06-13
MA31367B1 (fr) 2010-05-03
PL2146714T3 (pl) 2011-10-31
IL201448A0 (en) 2010-05-31
EP2146714A1 (fr) 2010-01-27
NZ580482A (en) 2011-10-28
JP2010524906A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2016179566A1 (en) Methods of treating a neurodegenerative disease
KR101503942B1 (ko) 파킨슨병과 관련된 운동 장애의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
AU764304B2 (en) Use of saredutant and of its pharmaceutically acceptable salts for the preparation of medicinal products that are useful in the treatment or prevention of major depressive disorders
US8592443B2 (en) Use of 4 cyclopropylmethoxy-N-(3,5 dichloro-1 oxido-pyridin-4 yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of spinal cord traumas
KR101460828B1 (ko) 두개골 외상의 치료를 위한 4-시클로프로필메톡시-ｎ-(3,5-디클로로-1-옥시도피리딘-4-일)-5-(메톡시)피리딘-2-카르복스아미드의 용도
HK1141725B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for preparing a medicament in the treatment of motor disorders related to parkinson's disease
HK1141724B (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141124

Application number text: 1020097021593

Filing date: 20091016

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141224

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150119

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150721

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I